Opinion - Lawmakers can help usher in a golden age by extending Opportunity Zones
With the passage of the House reconciliation bill, the majority party is working on sending one 'big, beautiful bill' to the Oval Office. While Medicare debates dominated the budget conversation, President Trump's 'number one economic development project ever in our country,' Opportunity Zones, is uniting lawmakers across the aisle.
One of the administration's key achievements was a first-of-its-kind tax incentive designed to uplift the nation's most vulnerable communities. Known as the Opportunity Zones tax incentive, the federal program gave working-class Americans a chance to benefit from a growing economy — many of whom had been overlooked during the 2008 financial crisis.
Opportunity Zones leverage capital gains that otherwise would remain on the sidelines in investors' portfolios, deploying those gains into low-income neighborhoods desperate for capital to come — and stay — in their communities. If investors keep their funds in these communities for 10 years, the gains are tax-free, a win-win for investors and residents of low-income neighborhoods.
The bipartisan initiative flooded low-income communities with private capital and helped breathe life into previously neglected neighborhoods. Now, Congress should prioritize expanding Opportunity Zones or making the tax incentive permanent, ensuring that funding continues to reach the nation's underserved communities.
Since its 2017 inception, the program has been a success. The results speak for themselves.
Opportunity Zones have raised employment growth by 3 to 4.5 percentage points in OZ communities relative to similar non-OZ areas. Corporations and manufacturers made massive investments domestically that created good-paying jobs for millions of Americans.
According to a 2022 report from the Joint Committee on Taxation, Qualified Opportunity Zone Funds have raised more than $85 billion in equity — with another three years of investment beyond that. Over half of this money has gone toward new housing projects alone — a victory for families working hard to achieve the American dream of homeownership.
Previously overlooked communities like Erie, Pa. — once home to one of the poorest ZIP codes in America — benefitted from Opportunity Zones. Erie alone saw over $400 million in new, long-term capital investment, with similar success stories across all 50 states and territories.
The federal incentive doesn't dictate where investments should go; instead, it empowers communities to develop the resources they need. While Opportunity Zones have significantly expanded housing stock, they have also spurred major investments in new businesses, industrial revitalization and manufacturing development.
Projects have ranged from research and development labs, and academic spaces to more localized initiatives like constructing a grocery store in a former food desert. Other examples include the launch of a 5G technology manufacturing center and the transformation of long-vacant buildings into job training hubs, employment centers and entrepreneurship incubators.
The incentive benefits rural communities, too. In Eastern North Carolina, Promised Land's Opportunity Zone fund has invested in a 4,000-acre working farm that produces potatoes, corn and soybeans on a massive scale, adding a $4 million state of the art grain bin system. The farm improved its long-term productivity and, importantly, the community's economic sustainability.
These projects are crucial as nearly 40 million Americans live in poverty and grapple with high living costs and limited access to economic opportunities. Opportunity Zones align their needs with investors searching for new opportunities as they navigate a volatile stock market.
Before the Opportunity Zones program was imagined, President Trump reshaped the skylines of our nation's busiest hubs — changing their trajectory in the process. That same legacy lives on through this important initiative — only this time touching more communities than ever before. Federal lawmakers should make it a priority to extend or make permanent the Opportunity Zones program.
Shay Hawkins is deputy director for Opportunity Zones at America First Policy Institute. Jill Homan is advisor for Opportunity Zones at America First Policy Institute.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
16 minutes ago
- Los Angeles Times
China says U.S. moves on computer chips and student visas ‘seriously violate' tariffs truce
TAIPEI, Taiwan — China criticized the U.S. on Monday over moves it alleged harmed Chinese interests, including issuing AI chip export control guidelines, stopping the sale of chip design software to China, and planning to revoke Chinese student visas. 'These practices seriously violate the consensus,' the Commerce Ministry said in a statement, referring to a China-U.S. joint statement in which the United States and China agreed to slash their massive recent tariffs, restarting stalled trade between the world's two biggest economies. But last month's de-escalation in President Trump's trade wars did nothing to resolve underlying differences between Beijing and Washington and Monday's statement showed how easily such agreements can lead to further turbulence. The deal lasts 90 days, creating time for U.S. and Chinese negotiators to reach a more substantive agreement. But the pause also leaves tariffs higher than before Trump started ramping them up last month. And businesses and investors must contend with uncertainty about whether the truce will last. U.S. Trade Representative Jamieson Greer said the U.S. agreed to drop the 145% tax Trump imposed last month to 30%. China agreed to lower its tariff rate on U.S. goods to 10% from 125%. The Commerce Ministry said China held up its end of the deal, canceling or suspending tariffs and non-tariff measures taken against the U.S. 'reciprocal tariffs' following the agreement. 'The United States has unilaterally provoked new economic and trade frictions, exacerbating the uncertainty and instability of bilateral economic and trade relations,' while China has stood by its commitments, the statement said. It also threatened unspecified retaliation, saying China will 'continue to take resolute and forceful measures to safeguard its legitimate rights and interests.' Trump stirred further controversy Friday, saying he will no longer be nice with China on trade, declaring in a social media post that the country had broken an agreement with the United States. Hours later, Trump said in the Oval Office that he will speak with Chinese President Xi Jinping and 'hopefully we'll work that out,' while still insisting China had violated the agreement. 'The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US,' Trump posted. 'So much for being Mr. NICE GUY!' In response to recent comments by Trump, the Commerce Ministry said of the U.S.: 'Instead of reflecting on itself, it has turned the tables and unreasonably accused China of violating the consensus, which is seriously contrary to the facts.' U.S. Commerce Secretary Howard Lutnick said that the Chinese were 'just slow rolling the deal' from Geneva. Appearing on Fox News on Sunday, Lutnick said the U.S. was 'taking certain actions to show them what it feels like on the other side of that equation,' adding that Trump would 'work it out' with Xi. The Trump administration also stepped up the clash with China in other ways last week, announcing that it would start revoking visas for Chinese students studying in the U.S. U.S. campuses host more than 275,000 students from China. Both countries are in a race to develop advanced technologies such as artificial intelligence, with Washington seeking to curb China's access to the most advanced computer chips. China is also seeking to displace the U.S. as the leading power in the Asia-Pacific, including through gaining control over close U.S. partner and leading tech giant Taiwan. Bodeen writes for the Associated Press.
Health Line
16 minutes ago
- Health Line
Does Medicare Cover Trulicity?
Medicare Part D plans and some Part C plans may cover Trulicity (dulaglutide) for diabetes, but the exact coverage depends on the plan. Such plans will only cover this drug for weight loss in certain cases if you're living with obesity. Trulicity (dulaglutide) is a drug belonging to the glucagon-like peptide-1 receptor agonist (GLP-1) class of medications. Diabetes affects 38.4 million people in the United States, or 11.6% of the population. The Food and Drug Administration (FDA) has approved this drug to help manage type 2 diabetes and reduce the chance of developing heart disease. For this reason, although GLP-1s may be prescribed off-label for weight loss, Medicare Part D plans may cover this drug for diabetes management but not for weight loss, except under specific circumstances. Is Trulicity covered by Medicare Part B? Medicare is generally divided into the following parts: Original Medicare (parts A and B) Medicare Part D Medicare Part C (Medicare Advantage) Medigap Part B Part B mainly covers medications that you cannot administer yourself, such as IV infusions, for example. While Trulicity is an injection drug, it is one that you can inject yourself. For this reason, Medicare Part D would be responsible for covering a drug like Trulicity. Part D Since private insurers manage Part D plans, the exact drugs that each plan covers vary. What drugs a specific plan covers depends on its formulary, which is a list of the covered drugs. Part D plans are generally required to cover at least two drugs from the most commonly prescribed categories. If the plan does not cover Trulicity (dulaglutide), it is likely to cover some brand-name or generic alternative. Medicare's plan finder tool allows you to enter medications you take to see which Part D plans in your area include these medications in their formulary. The tool also lets you compare prices at different pharmacies in your area. Part C Medicare Part C, also called Medicare Advantage, is another option for healthcare coverage under Medicare. These optional, private plans offer the same benefits as Original Medicare. Some Part C plans may also offer other benefits, such as prescription drug coverage. Coverage for specific medications under a Medicare Advantage plan depends on the options and plans that the company you choose offers. When selecting a Medicare Advantage plan, you can specify medications you take to compare coverage and pricing. Why doesn't Medicare cover Trulicity for weight loss? Medicare drug plans typically cover medications when they are considered medically necessary. Therefore, Part D plans or Part C plans with drug coverage won't cover GLP-1 agonists like Trulicity for weight loss. Typically, coverage focuses on FDA-approved uses such as helping manage type 2 diabetes or lowering cardiovascular risks for overweight adults or those living with obesity. Obesity is defined as having a body mass index (BMI) of 30 or greater. This means you could have a BMI between 25 and 30, but would not qualify for a drug like Trulicity through Medicare unless you need it for diabetes. Under the Biden administration, the Centers for Medicare & Medicaid Services (CMS) looked into expanding coverage of GLP-1 drugs for weight loss by 2026. However, the Trump administration has since decided against this expansion. How much does Trulicity cost on Medicare? Trulicity's list price is $987.19 per month, but insurance or Medicare coverage may lower this cost. When a Medicare drug plan covers a drug, how much you'll pay out of pocket depends on the tier your plan classifies the drug within its formulary. Generally, higher-tier drugs cost more. Copays for this medication will vary based on the plan you choose, but the manufacturer suggests a range of $0 to $100 per month after you've met your Medicare Part D deductible. Generic drugs are generally classified in a lower tier, but no generic Trulicity is currently available. How can I lower the cost of Trulicity? Trulicity's manufacturer offers a savings card through which you can get a one-month supply of Trulicity for as little as $25. However, you won't be able to use your Medicare plan if you want this discount. Alternatively, you can check whether you qualify for Extra Help, which can lower your prescription costs to $4 to $9. Other resources for lowering drug costs include: Other tips that may help lower your prescription drug costs include: Ask your doctor about less expensive generic options. Consider switching from a 30-day supply to a 90-day supply for your medications, as buying a larger supply upfront can provide cost savings. Consider a mail-order supplier to save on costs. What is a cheaper alternative to Trulicity? The following chart shows GLP-1 agonists currently available in the United States and their brand-name retail prices before insurance. Available generic versions usually cost less. Brand name (generic name) List price as of 2025 Wegovy (semaglutide) $1,349.02 Ozempic (semaglutide) $997.58 Rybelsus (semaglutide $997.58 Mounjaro (tirzepatide) $1,079.77 Zepbound (tirzepatide) $1,086.37 Saxenda (liraglutide) $1,349.02 Victoza (liraglutide) $543.51 or $815.27 (depending on dose) Trulicity (dulaglutide) $987.19 In addition, other diabetes medications can be covered by Medicare. CMS included several of these drugs in the list of 10 drugs it used to renegotiate prices as part of the Inflation Reduction Act of 2022. Takeaway Trulicity is a long-lasting brand-name medication that can be quite effective at lowering high blood sugar levels due to type 2 diabetes. It is not a substitute for insulin or diet and lifestyle strategies for managing diabetes. There is no generic version of this medication. It is typically a tier 3 medication in most drug plan formulary lists. Many Medicare Part D plans include Trulicity on formularies, but you'll likely still pay a share of the costs. The cost you'll pay will depend on your specific plan. A variety of private and public programs offer extra help in covering your medication costs. You can also talk with your doctor about an affordable way to manage diabetes. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Chicago Tribune
19 minutes ago
- Chicago Tribune
China says US moves on computer chips and student visas ‘seriously violate' tariffs truce
TAIPEI, Taiwan — China criticized the U.S. on Monday over moves it alleged harmed Chinese interests, including issuing AI chip export control guidelines, stopping the sale of chip design software to China, and planning to revoke Chinese student visas. 'These practices seriously violate the consensus,' the Commerce Ministry said in a statement, referring to a China-U.S. joint statement in which the United States and China agreed to slash their massive recent tariffs, restarting stalled trade between the world's two biggest economies. But last month's de-escalation in President Donald Trump's trade wars did nothing to resolve underlying differences between Beijing and Washington and Monday's statement showed how easily such agreements can lead to further turbulence. The deal lasts 90 days, creating time for U.S. and Chinese negotiators to reach a more substantive agreement. But the pause also leaves tariffs higher than before Trump started ramping them up last month. And businesses and investors must contend with uncertainty about whether the truce will last. U.S. Trade Representative Jamieson Greer said the U.S. agreed to drop the 145% tax Trump imposed last month to 30%. China agreed to lower its tariff rate on U.S. goods to 10% from 125%. The Commerce Ministry said China held up its end of the deal, canceling or suspending tariffs and non-tariff measures taken against the U.S. 'reciprocal tariffs' following the agreement. 'The United States has unilaterally provoked new economic and trade frictions, exacerbating the uncertainty and instability of bilateral economic and trade relations,' while China has stood by its commitments, the statement said. It also threatened unspecified retaliation, saying China will 'continue to take resolute and forceful measures to safeguard its legitimate rights and interests.' Trump stirred further controversy Friday, saying he will no longer be nice with China on trade, declaring in a social media post that the country had broken an agreement with the United States. Hours later, Trump said in the Oval Office that he will speak with Chinese President Xi Jinping and 'hopefully we'll work that out,' while still insisting China had violated the agreement. 'The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US,' Trump posted. 'So much for being Mr. NICE GUY!' In response to recent comments by Trump, the Commerce Ministry said of the U.S.: 'Instead of reflecting on itself, it has turned the tables and unreasonably accused China of violating the consensus, which is seriously contrary to the facts.' U.S. Commerce Secretary Howard Lutnick said that the Chinese were 'just slow rolling the deal' from Geneva. Appearing on Fox News on Sunday, Lutnick said the U.S. was 'taking certain actions to show them what it feels like on the other side of that equation,' adding that Trump would 'work it out' with Xi. The Trump administration also stepped up the clash with China in other ways last week, announcing that it would start revoking visas for Chinese students studying in the U.S. U.S. campuses host more than 275,000 students from China. Both countries are in a race to develop advanced technologies such as artificial intelligence, with Washington seeking to curb China's access to the most advanced computer chips. China is also seeking to displace the U.S. as the leading power in the Asia-Pacific, including through gaining control over close U.S. partner and leading tech giant Taiwan.
